Oscar Health, Inc. (OSCR): A Bull Case Theory 

We came across a bullish thesis on Oscar Health, Inc. on Deep Value Returns’s Substack. In this article, we will summarize the bulls’ thesis on OSCR. Oscar Health, Inc.’s share was trading at $19.28 as of October 2nd.

Oscar Health, Inc. (OSCR) has faced challenges recently, particularly due to high medical loss ratios that weighed on performance in Q2 2025, making it a disappointing recommendation in the near term. However, the current market discount presents a renewed opportunity, as these near-term issues are largely priced in. Looking ahead to 2026, the company is set to benefit from across-the-board premium increases, which should drive approximately 5% topline growth.

This anticipated revenue growth provides a clear catalyst for the stock, which is currently trading at a deeply discounted 0.4x sales multiple. As investors recognize the improving fundamentals and margin recovery, a re-rating of the stock is likely, unlocking substantial upside potential. Based on these dynamics, a price target of $30 per share by the end of 2026 appears achievable, reflecting the market’s likely recognition of Oscar’s earnings improvement and growth trajectory. The combination of near-term issues being addressed and medium-term revenue growth sets the stage for a compelling risk/reward profile for investors, making OSCR an attractive opportunity despite recent underperformance.

Previously we covered a bullish thesis on Oscar Health, Inc. (OSCR) by convexititties in March 2025, which highlighted ACA-related fears being priced in, strong insider confidence, and AI-driven technology supporting EPS growth to $2.25–$3.00 by 2027. The stock has appreciated ~25% since coverage. This is because near-term fears partially played out. Deep Value Returns shares a similar perspective but emphasizes near-term medical loss ratio challenges and 2026 premium-driven growth.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.